Dr. Paul A Krogstad, MD

Dr. Paul Krogstad attended UCLA and received his Bachelor of Science in Cybernetics and a Master's Degree in Engineering. After leaving Los Angeles, he attended the Tulane University School of Medicine in New Orleans, Louisiana, where he also completed his training in Pediatrics.

He trained as a specialist in Pediatric Infectious Diseases at the University of Washington in Seattle, then returned to UCLA for additional postdoctoral training in human retrovirology. He joined the UCLA faculty in 1992 and is now a Professor in the departments of Pediatrics and Pharmacology, and serves as the Director of the Fellowship Program in Pediatric Infectious Diseases.

Dr. Krogstad's laboratory focuses on molecular virology and the pathogenesis of viral diseases. His studies of HIV pathogenesis currently include evaluation of the impact of HIV on T cell production and immunological ontogeny in HIV infected children and adolescents. His laboratory research also includes molecular approaches to the …identification of cellular factors involved in coxsackievirus replication and the immunological and viral contributions to the pathogenesis of enteroviral myocarditis. In addition, he has led and collaborated in several studies of new drugs for the treatment of HIV and enteroviral infection.

Memberships, Major Commitees
Member, Department of Health and Human Services (HHS) Panel on Antiretroviral Therapy and Medical Management of HIV-Infected Children , 2007- present

Programs
Site Investigator: Collaborative Antiviral Study Group Protocol 106.

Laboratory Research
HIV immunopathogenesis - Research conducted in 2010-2011 focused on examining perturbations of T cell receptor populations among HIV infected adolescents and adults. Within the IMPAACT research network, I have obtained approval for a retrospective analysis of the clinical significance of persistent CD4 lymphocytopenia in children with successful suppression of HIV by antiretroviral therapy.

HIV therapy - Obtained approval from IMPAACT network to go forward with protocol development for P1101, a Phase I/II study of raltegravir as part of HAART in HIV infected children with TB coinfection.

Enterovirus Replication and pathogenesis. In studies being conducted by Dr. Susan Wollersheim, we have examined the
Molecular epidemiology of picornaviruses. Dr. Susan Wollersheim is using molecular phylogenetic methods to identify picornaviruses (enteroviruses and rhinoviruses) detected by multiplex PCR methods in the UCLA Clinical Microbiology Laboratory. We hope to determine if the reported high frequency of detection of the nucleaic acid of rhinoviruses and human enteroviruses in respiratory virus specimens reflects dual infection or imprecision on the part of the commercial methodology being used.

Antiviral agents for enterovirus infection. Two distinct approaches are being used in efforts to identify antiviral therapies for enterovirus infection. In the first, we have used mass spectrometry to identify cellular proteins involved in translation of the enterovirus genome under the control of the viral Internal Ribosome Entry Site. In the second, we are performing high throughput screeningof chemical libraries to identify inhibitors of lytic replication of enterovirus agents.

Genetic basis for disseminated coccidioidomycosis: conducted pilot study to demonstrate utility of archived pathology specimens to as source of DNA to identify genetic polymorphisms associated with dissemination of coccidioidomycosis in African Americans. (Presented at 55th Annual Meeting of the Coccidioidomycosis Study Group. Davis CA. April, 2011.)

Fellowship Program
Director

Service to Hospital, Medical School, and UCLA AIDS Institute.